Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 19/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3570539 | 1.00 | PTPRB (0.52) | PTPRBCA1CA2CA9 | |
| SCHEMBL468168 | 0.89 | PTPRB (0.52) | PTPRB | |
| SCHEMBL468167 | 0.89 | PTPRB (0.52) | PTPRB | |
| SCHEMBL468290 | 0.85 | PTPRB (0.50) | PTPRBCA1CA2CA9 | |
| SCHEMBL468292 | 0.85 | PTPRB (0.50) | PTPRBCA1CA2CA9 | |
| SCHEMBL3925319 | 0.85 | PTPRB (0.45) | PTPRB | |
| SCHEMBL27750693 | 0.85 | PTPRB (0.52) | PTPRB | |
| SCHEMBL468383 | 0.84 | PTPRB (0.73) | PTPRB | |
| SCHEMBL468385 | 0.84 | PTPRB (0.73) | PTPRB | |
| SCHEMBL3570542 | 0.83 | PTPRB (0.74) | PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130324558-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-12-05 | — | — | US | claimed |
| US-20130096140-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-04-18 | — | — | US | claimed |
| US-20100016336-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2010-01-21 | — | — | US | claimed |
| US-20080108631-A1 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-08 | — | — | US | claimed |
| US-20220378750-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2022-12-01 | — | — | US | disclosed |
| US-20220117946-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2022-04-21 | — | — | US | disclosed |
| EP-3323815-B1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS LLC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200253936-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2020-08-13 | — | — | US | disclosed |
| US-10463650-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Aerpio Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180221346-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2018-08-09 | — | — | US | disclosed |
| EP-3323815-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | Aerpio Therapeutics, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |
| US-RE46592-E1 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20140221666-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130324558-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-12-05 | — | — | US | disclosed |
| EP-2592072-A2 | Human protein tyrosine phosphatase inhibitors and their use | Warner Chilcott Company, LLC (PR) | 2013-05-15 | — | — | EP | disclosed |
| US-20130096140-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130023543-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-8258311-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100069448-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2010-03-18 | — | — | US | disclosed |
| US-20080108631-A1 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096140-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CA1 3720/4885CA2 2212/4885 |
| US-20100016336-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CA1 3720/4885CA2 2212/4885 |
| US-20220117946-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CA1 3720/4885CA2 2212/4885 |
| US-10463650-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CA1 3720/4885CA2 2212/4885 |
| US-20130023543-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CA1 3720/4885CA2 2212/4885 |
| US-20200253936-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CA1 3720/4885CA2 2212/4885 |
| US-20100069448-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CA1 3720/4885CA2 2212/4885 |
| US-20080108631-A1 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | VASP, DUSP15, PPP5C | PTPRB 63/4885CA1 2743/4885CA2 910/4885 |
| US-20140221666-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CA1 3720/4885CA2 2212/4885 |
| US-20220378750-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CA1 3720/4885CA2 2212/4885 |
| US-20180221346-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CA1 3720/4885CA2 2212/4885 |
| US-20130324558-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885CA1 3720/4885CA2 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.